News | Radiation Therapy | October 25, 2017

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer

Study indicates higher dosing enabled by MR-guidance combined with daily on-table adaptation led to significant potential clinical benefits for pancreatic cancer patients

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer
MRIdian MRI-guided radiotherapy overall survival for pancreatic cancer patients

Early clinical data suggests nearly 2X prolonged median survival for inoperable, locally advanced pancreatic cancer with MRIdian MR-Guided Radiation Therapy. Image from “Higher Maximum Biological Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable Pancreatic Cancer Patients. Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel A, Parikh P, Bassetti, M, Lee P, ASTRO 2017”

October 25, 2017 — ViewRay Inc. announced outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego. This data highlighted compelling early results using the company's magnetic resonance imaging (MRI)-guided MRIdian radiation therapy system for the treatment of inoperable, locally advanced pancreatic cancer.

MRIdian allows clinicians to see the tumor and nearby soft-tissue anatomy throughout radiation treatments using real-time diagnostic MR-visualization. As a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor. By more accurately targeting the tumor, and reducing treatment radiation dose to surrounding organs such as the duodenum, small bowel, stomach and liver, a higher and potentially more effective radiation dose may be delivered without increasing the risks of side effects and complications for the patient.

As featured in the ASTRO Scientific Session poster titled "High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer," key data points and findings from the presentation include the following:

  • The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University);
  • The authors examined survival and toxicity rates for two unique cohorts of patients. One sample received a higher biologically effective dose (maxBED10 >90), primarily enabled by MRIdian MR-guided on-table adaptive radiotherapy. The other sample received a lower, more conventional biologically effective dose (maxBED10 <90), using non-adaptive therapy;
  • The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months); and
  • Patients treated with higher radiation doses reported no grade 3 or higher toxicities (0 percent). In comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.

"High-definition MR now enables oncologists to detect the slightest anatomical changes that occur from one day to the next and in real-time while the patient is being treated. Coupled with new adaptive radiation therapy software tools, we create new customized plans in minutes, all while the patient is on the treatment table," said Percy Lee, M.D., senior author and associate professor and vice chair of education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. "The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile. These outcomes warrant further investigations."

The early results highlighted above, along with other data obtained using MRIdian, will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer. The trial will be conducted by ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian medical institutions focused on evidence gathering to support MR-guided radiation therapy.

For more information: www.viewray.com

Related MRI-Guided Radiotherapy Content

WEBINAR: Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...